CAS: 23288-49-5; 4,4'-(Propane-2,2-Diylbis(Sulfanediyl))Bis(2,6-Di-Tert-Butylphenol)

上下游产品

CAS号950-59-4 2,6-二叔丁基-4-巯基苯酚 | CAS号67-64-1 丙酮 | CAS号110-94-1 戊二酸 | CAS号719-22-2 2,6-二叔丁基苯醌 | CAS号6386-58-9 双(3,5-二叔丁基苯-4-醇)二硫化物 | CAS号6386-61-4 2,6-ditert-buty... | CAS号2455-14-3 3,3',5,5'-四叔丁基-... | CAS号216167-82-7 Succinobucol | CAS号216168-45-5 Probucol disuccinate | CAS号216167-95-2 4-(2,6-二-叔丁基-4-... | CAS号110-15-6 琥珀酸； 丁二酸

Probucol Radical置于2,6-二叔丁基-4-(3,5-二叔丁基-4-羟基苯亚甲基)-2,5-环己二烯-1-酮体系中,用 甲苯 用作溶剂,化学反应生成普罗布考
参考文献:Bond Dissociation Enthalpy Of .Alpha.-Tocopherol And Other Phenolic Antioxidants
标题:Bond Dissociation Enthalpy Of .Alpha.-Tocopherol And Other Phenolic Antioxidants
摘要:The Equilibrium Constants,K-1,For The Reaction Between Galvinoxyl And A Series Of Phenolic Antioxidants Have Been Determined By Means Of Epr Spectroscopy. With Aroxyl Radicals Decaying At Appreciable Rates,K-1 Was Obtained By Performing Kinetic Analyses Of The Time Dependence Of The Concentrations Of The Equilibrating Radicals After Mixing The Reactants. In Two Cases The Temperature Dependence Of K-1 Was Also Studied And The Entropy Change For The Equilibration Reaction Was Determined. Bond Dissociation Enthalpies,Dh,Of The Aro-H Bond Of The Examined Phenols Were Calculated By Comparison With The Known Value Of 2,4,6-Tri-Tert-Butylphenol (81.24 Kcal Mol(-1)). A Larger Than Expected Dh Value Was Found For Probucol (81.03 Kcal Mol(-1)) And An Explanation Of This Behavior Was Given In Terms Of The Preferred Conformation Adopted By The Para Alkylthio Group. The Dh Value Of Alpha-Tocopherol (78.93 Kcal Mol(-1)) Was Found To Be Very Close To That Of The Phenolic Precursor Of Galvinoxyl (78.80 Kcal Mol(-1)) And Somewhat Larger Than That Of 2,6-Di-Tert-Butyl-4-Methoxyphenol (77.61 Kcal Mol(-1)).
Doi:10.1021/jo00096A061

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-5656662-A
优先权日:1990-01-12
标 题:Synthesis of optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids
发明人：MANTRI PADMAJA; WITIAK DONALD T
权利人:UNIV OHIO STATE RES FOUND
摘要:The present invention relates to a method for synthesis of optically pure 4-alkenyl or 4-alkanyl-2-hydroxytetronic acids from an optically pure aldehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, thus making them useful in the treatment of coronary artery diseases, especially atherosclerosis, and additionally, as inhibitors of various inflammatory cytokines, making them useful in the treatment of both acute and chronic inflammation, as well in the treatment of cachexia, rheumatoid arthritis, multiple sclerosis, Crohn's disease and ulcerative colitis. The invention further relates to pharmaceutical compositions of the instant compounds.

专利号:US-2002022022-A1
优先权日:2000-05-19
标题 :Inhibition of cell proliferation and matrix synthesis by antioxidants and NAD(P)H oxidase inhibitors
发明人：SHI YI; ZALEWSKI ANDREW
摘要:The present invention is directed to a method for the prophylactic and therapeutic treatment of diseases or disorders associated with the abnormal proliferation and extracellular matrix synthesis of smooth muscle cells (SMC) and fibroblasts due to activation of NAD(P)H and/or increased ROS generation. The method involves the administration of an NAD(P)H oxidase inhibitor(s) and/or antioxidant(s) to a mammal in an amount sufficient to treat the disease or disorder prophylactically or therapeutically. The NAD(P)H oxidase inhibitor inhibits the synthesis or translocation of NAD(P)H subunits, thereby blocking the generation of intracellular reactive oxygen species (ROS) and thus the proliferation and extracellular matrix synthesis of SMC and fibroblasts. Similarly, the administration of antioxidants blocks the generation of intracellular ROS, thereby inhibiting SMC and fibroblast proliferation and extracellular matrix synthesis. In addition to the prevention and treatment of vascular disease, such as atherosclerosis, graft disease, and restenosis, NAD(P)H oxidase inhibitors and antioxidants may be useful for the prevention and treatment of other conditions by decreasing cell proliferation and extracellular matrix synthesis associated therewith. These conditions include arthritis, keloid formation, cancer, tissue and organ fibrosis, and complications related to organ transplantation, metabolic syndrome, and radiation therapy.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-2013243770-A1
优先权日:2005-10-14
标 题:Treating diabetes using inhibitors of il-1
发明人：LAU JESPER
权利人:NOVO NORDISK AS
摘要:The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.